• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

绘制第五版世界卫生组织乳腺肿瘤分类中导管原位癌的引用证据图谱。

Mapping the cited evidence of ductal carcinoma in situ from the 5th edition of the World Health Organisation classification of tumours of the breast.

机构信息

Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.

Singapore Breast Surgery Center, Singapore, Singapore.

出版信息

Histopathology. 2024 Sep;85(3):510-520. doi: 10.1111/his.15279. Epub 2024 Jul 18.

DOI:10.1111/his.15279
PMID:39030792
Abstract

AIMS

Ductal carcinoma in situ (DCIS) is recognised by the World Health Organisation (WHO) Classification of Tumours (WCT) as a non-invasive neoplastic epithelial proliferation confined to the mammary ducts and lobules. This report categorises the references cited in the DCIS chapter of the 5th edition of the WCT (Breast Tumours) according to prevailing evidence levels for evidence-based medicine and the Hierarchy of Evidence for Tumour Pathology (HETP), identifying potential gaps that can inform subsequent editions of the WCT for this tumour.

METHODS AND RESULTS

We included all citations from the DCIS chapter of the WCT (Breast Tumours, 5th edition). Each citation was appraised according to its study design and evidence level. We developed our map of cited evidence, which is a graphical matrix of tumour type (column) and tumour descriptors (rows). Spheres were used to represent the evidence, with size and colour corresponding to their number and evidence level respectively. Thirty-six publications were retrieved. The cited literature in the DCIS chapter comprised mainly case series and were regarded as low-level. We found an unequal distribution of citations among tumour descriptors. 'Pathogenesis' and 'prognosis and prediction' contained the most references, while 'clinical features', 'aetiology' and 'diagnostic molecular pathology' had only a single citation each. 'Prognosis and prediction' had the greatest proportion of moderate- and high-levels of evidence.

CONCLUSION

Our findings align with the disposition for observational studies inherent in the field of pathology. Our map is a springboard for future efforts in mapping all available evidence on DCIS, potentially augmenting the editorial process and future editions of WCTs.

摘要

目的

世界卫生组织(WHO)肿瘤分类(WCT)将导管原位癌(DCIS)定义为一种局限于乳腺导管和小叶的非浸润性肿瘤性上皮增生。本报告根据循证医学的现行证据水平和肿瘤病理学证据分级(HETP),对 WCT(乳腺肿瘤)第 5 版 DCIS 章节中引用的参考文献进行分类,确定可能为该肿瘤的 WCT 后续版本提供信息的潜在差距。

方法和结果

我们纳入了 WCT(乳腺肿瘤,第 5 版)DCIS 章节中的所有参考文献。根据研究设计和证据水平对每个参考文献进行评估。我们制定了引用证据图谱,这是一个肿瘤类型(列)和肿瘤描述符(行)的图形矩阵。使用球体代表证据,大小和颜色分别对应于它们的数量和证据水平。检索到 36 篇出版物。DCIS 章节中引用的文献主要是病例系列,被认为是低水平的。我们发现肿瘤描述符之间的引用分布不均。“发病机制”和“预后和预测”包含最多的参考文献,而“临床特征”、“病因”和“诊断分子病理学”每个仅引用一次。“预后和预测”具有最多的中高级别证据。

结论

我们的发现与病理学领域中观察性研究的倾向一致。我们的图谱为未来努力绘制 DCIS 所有可用证据提供了基础,可能会增强编辑过程和 WCT 的未来版本。

相似文献

1
Mapping the cited evidence of ductal carcinoma in situ from the 5th edition of the World Health Organisation classification of tumours of the breast.绘制第五版世界卫生组织乳腺肿瘤分类中导管原位癌的引用证据图谱。
Histopathology. 2024 Sep;85(3):510-520. doi: 10.1111/his.15279. Epub 2024 Jul 18.
2
Phyllodes tumour evidence gaps mapped from the 5th edition of the WHO classification of tumours of the breast.叶状肿瘤证据差距从第 5 版世卫组织乳腺肿瘤分类映射。
Histopathology. 2023 Apr;82(5):704-712. doi: 10.1111/his.14856. Epub 2023 Jan 30.
3
Exploratory evidence maps for the WHO Classification of Tumours 5th edition for lung and thymus tumors.探索性证据图谱为第五版世界卫生组织肿瘤分类的肺和胸腺肿瘤。
Virchows Arch. 2024 Nov;485(5):869-878. doi: 10.1007/s00428-024-03886-6. Epub 2024 Oct 25.
4
Understanding the use of evidence in the WHO Classification of Tumours: a protocol for an evidence gap map of the classification of tumours of the lung.理解世卫组织肿瘤分类中证据的应用:对肺癌肿瘤分类的证据差距图的制定方案。
BMJ Open. 2022 Oct 11;12(10):e061240. doi: 10.1136/bmjopen-2022-061240.
5
Ductal carcinoma in situ: terminology, classification, and natural history.导管原位癌:术语、分类及自然史
J Natl Cancer Inst Monogr. 2010;2010(41):134-8. doi: 10.1093/jncimonographs/lgq035.
6
Ductal carcinoma in situ of the breast: a new phenotype classification system and its relation to prognosis.乳腺导管原位癌:一种新的表型分类系统及其与预后的关系。
Breast Cancer Res Treat. 2002 Jun;73(3):215-21. doi: 10.1023/a:1015816406078.
7
Classification of ductal carcinoma in situ by gene expression profiling.通过基因表达谱对导管原位癌进行分类。
Breast Cancer Res. 2006;8(5):R61. doi: 10.1186/bcr1613.
8
Invasive ductal carcinoma with coexisting ductal carcinoma in situ (IDC/DCIS) versus pure invasive ductal carcinoma (IDC): a comparison of clinicopathological characteristics, molecular subtypes, and clinical outcomes.伴导管原位癌成分的浸润性导管癌(IDC/DCIS)与单纯浸润性导管癌(IDC)的比较:临床病理特征、分子亚型和临床结局的比较。
J Cancer Res Clin Oncol. 2019 Jul;145(7):1877-1886. doi: 10.1007/s00432-019-02930-2. Epub 2019 May 14.
9
Papillary carcinoma of the breast: diagnostic agreement and management implications.乳腺乳头状癌:诊断一致性及管理意义
Histopathology. 2016 Nov;69(5):862-870. doi: 10.1111/his.13009. Epub 2016 Aug 1.
10
Impact of microinvasion on breast cancer mortality in women with ductal carcinoma in situ.微浸润对导管原位癌女性乳腺癌死亡率的影响。
Breast Cancer Res Treat. 2018 Feb;167(3):787-795. doi: 10.1007/s10549-017-4572-2. Epub 2017 Nov 8.